Novel crystalline polymorphs of 1-[(3r)-3-[4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one and process for preparation thereof
AssigneeMsn Laboratories Private Limited, R&D Center
InventorsThirumalai Rajan SRINIVASAN, Eswaraiah SAJJA, Vijayavitthal T MATHAD, Rajeshwar Reddy SAGYAM, Srinivasulu RANGINENI, Venkata Narasayya SALADI
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel crystalline polymorphs of 1-[(3R)-3-[4-amino-3(4-phenoxy phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one represented by the following structural formula-1 and process for preparation thereof.
Claims37
A crystalline form-M1 of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one compound of formula-1 characterized by a PXRD pattern in accordance with FIG. 1.
A process for the preparation of crystalline form-M1 of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one compound of formula-1, comprising:
- a) providing a solution of compound of formula-1 in isopropanol optionally in mixture with a first solvent,
- b) optionally filtering the obtained solution,
- c) combining the solution with a second solvent at a suitable temperature to provide crystalline form-M1 of compound of formula-1.
A crystalline form-M2 of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one compound of formula-1 characterized by a PXRD pattern in accordance with FIG. 2.
A process for preparation of crystalline form-M2 of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one compound of formula-1, comprising:
- a) providing a solution of compound of formula-1 in O-cresol,
- b) optionally filtering the obtained solution,
- c) combining the solution with a solvent at a suitable temperature to provide crystalline form-M2 of compound of formula-1.
A crystalline form-M3 of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one compound of formula-1 characterized by a PXRD pattern in accordance with FIG. 3.
A process for preparation of crystalline form-M3 of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one compound of formula-1, comprising:
- a) providing a solution of compound of formula-1 in benzyl alcohol,
- b) optionally filtering the obtained solution,
- c) combining the solution with a solvent at a suitable temperature to provide crystalline form-M3 of compound of formula-1.
A crystalline form-M4 of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one compound of formula-1 characterized by a PXRD pattern in accordance with FIG. 4.
A process for preparation of crystalline form-M4 of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one compound of formula-1, comprising:
- a) providing a solution of compound of formula-1 in methyl benzoate,
- b) optionally filtering the obtained solution,
- c) optionally combining the solution with a solvent at a suitable temperature to provide crystalline form-M4 of compound of formula-1.
A crystalline form-M5 of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one compound of formula-1 characterized by a PXRD pattern in accordance with FIG. 7.
The crystalline form-M5 of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one compound of formula-1 characterized by peaks at about 6.3, 10.0, 12.8, 13.7, 17.2, 18.1, 19.4, 20.2, 20.9, 21.6, 23.1, 23.7, 24.6, 26.2 and 27.7±0.2° of 2θ.
A process for the preparation of crystalline form-M5 of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one compound of formula-1, comprising:
- a) suspending compound of formula-1 and methyl paraben in a solvent,
- b) isolating crystalline form-M5 of compound of formula-1, and
- c) optionally slurrying the material in water.
A process for preparation of crystalline form-M5 of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one compound of formula-1, comprising:
- a) dissolving compound of formula-1 and methyl paraben in a solvent,
- b) optionally filtering the obtained solution, and
- c) isolating crystalline form-M5 of compound of formula-1.
A crystalline form-M6 of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one compound of formula-1 characterized by a PXRD pattern in accordance with FIG. 6.
A process for preparation of crystalline form-M6 of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one compound of formula-1, comprising:
- a) suspending compound of formula-1 and methyl paraben in a solvent, and
- b) isolating crystalline form-M6 of compound of formula-1.
A pharmaceutical composition comprising crystalline polymorph of compound of formula-1 of any of preceding claims and at least one pharmaceutically acceptable excipient.
A method of treating for the patients with Mental cell lymphoma or Chronic lymphocytic leukemia comprising administering to the said patient a therapeutically effective amount of crystalline polymorph of compound of formula-1 of any of preceding claims.
Dependencies are inferred from the claim text.